Merck CEO Kenneth Frazier said a flawed corporate tax system drives inversion deals that have drawn the government's ire. » Read More
Stocks close sharply lower amid a massive drop in technology stocks and concerns the Fed may raise rates this year.
U.S. stocks closed mostly higher on Wednesday, with the Dow and S&P completing a massive comeback spurred by a surge in oil.
U.S. stock index futures pointed to a mostly higher open on Wednesday after a better-than-expected ADP jobs report.
Some of the names on the move ahead of the open.
Merck reported a 2.5 percent fall in quarterly revenue, hurt by a strong dollar and declining sales of its Remicade arthritis treatment.
U.S. stock futures were higher this morning, following oil prices which were rising in early trading. The Dow dropped nearly 300 points Tuesday as U.S. crude tanked 5.5 percent.
Stocks enter the coming week on better footing, with economic data and earnings that could determine whether the economy is slowing.
With the earnings season in full swing, it's hard to keep track of who's reporting next. Luckily, CNBC's got you covered with this helpful look-ahead.
The rapid spread of the zika virus has spurred the hunt for a cure, but the financial incentive and likely length of time for a vaccine are unclear.
The "Fast Money" traders give their final trades of the day.
Karl-Ludwig Kley, chairman and CEO of Merck, is positive about the prospects for the health care and life sciences sector.
Regeneron CEO Len Schleifer says drug pricing needs to be balanced enough to support research and development.
Biotech stocks endured a rough Monday, and struggles may continue throughout the year for the high-growth sector, one trader said.
Jim Cramer provides his take on caller favorite stocks, including this popular technology play that can't be touched.
China volatility. Oil selling off. Geopolitical tensions. The year did not get off to a good start for investors.
Jan 7- Dynavax Technologies Corp said its experimental hepatitis B vaccine was found to be safe and effective in a late-stage study, paving the way for the company to resubmit its marketing application. The earlier marketing application for the vaccine, HEPLISAV-B, was rejected in February 2013 by the U.S. Food and Drug Administration, which sought additional...
There's a case to be made for the Dogs of the Dow, even as stocks start 2016 down. They offer yields that can pay off a mortgage.
U.S. stocks closed lower Wednesday in low volume trade as a decline in oil prices weighed.
The latest drug-price increases are just the tip of the iceberg, explains former Medtronic CEO Bill George.
*Zoetis, Pfizer assets could attract Bayer in future. Possible targets for the German company could include veterinary drug firm Zoetis and Pfizer's consumer health business, the two sources said. Bayer, Zoetis and Pfizer declined to comment.